PR Newswire Asia's news > Health Care/Hospital

 < Previous page   |   Title only   |   Print    Next page > 
     
AMI Pharm Advances AYP-101 to Phase 3, Paving the Way for a New Era in Fat-Reduction Injectable drugs
— Novel non-cytolytic injectable drug targets submental fat with significantly reduced pain and swelling — Phase 3 clinical trial underway in South Korea , following strong safety and efficacy results ...
2025-08-11T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
"Senior Speed Stack" Introduces Emerging Sport Stacking to Help Reduce Cognitive Decline in the Elderly
Key Points: ...
2025-08-11T    Health Care/Hospital   Sports 
Turtlebrace is now available through SPS and at Hanger Clinics Across the U.S.
MONTRÉAL , Aug. 11, 2025 /PRNewswire/ -- We're thrilled to announce that Turtlebrace will now be available through SPS , the largest supplier of orthotics and prosthetics (O&P) componentry ...
2025-08-11T    Computer/Electronics   Health Care/Hospital   Medical Equipment 
Everest Medicines to Announce 2025 Interim Results on August 29, 2025
SHANGHAI , Aug. 11, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, ...
2025-08-11T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
WuXi Biologics Launches HEK 293 Stable Cell Line Platform WuXia293 Stable for Development and Manufacturing of Difficult-to-Express Molecules
WuXia293 Stable  platform demonstrates high titer, human glycosylation and improved product quality by eliminating or significantly alleviating truncation in difficult-to-express molecules. WuXia293 ...
2025-08-11T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Akeso Announces First Patient Dosed in Phase III Trial of Ivonescimab as Consolidation Therapy for Limited-Stage SCLC After Definitive Radiotherapy
HONG KONG , Aug. 11, 2025 /PRNewswire/ --  Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its multicenter, randomized, double-blind ...
2025-08-11T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Philippines' AC Health partners with Singapore's ABC Impact in vision to transform health for every Filipino
MANILA, Philippines , Aug. 11, 2025 /PRNewswire/ -- AC Health, the healthcare arm of Ayala Corporation, has secured a landmark investment from ABC Impact, the Singapore -based impact investor dedicated ...
2025-08-11T    Health Care/Hospital   Medical/Pharmaceuticals 
HistoIndex Marks Another Step Forward with FibroSIGHT™ Plus: Introducing AI-based Quantitative Analysis in Fibrosis Assessment
SINGAPORE , Aug. 11, 2025 /PRNewswire/ -- HistoIndex, a pioneering leader in digital pathology solutions for chronic liver disease, has announced the launch of FibroSIGHT™ Plus , its second Laboratory ...
2025-08-11T    Biotechnology   Computer/Electronics   Health Care/Hospital   Medical Equipment 
Brain Navi Biotechnology's NaoTrac performs first surgeries in Spain
Brain Navi has officially landed in Spain ! ...
2025-08-11T    Biotechnology   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Hugel launches botulinum toxin Letybo in Malaysia
- The company strengthens brand experience for local medical professionals through academic events and hands-on workshops ...
2025-08-11T    Health Care/Hospital   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.